DashboardAll companies
Run this on your own research
Healthcare · Drug Manufacturers - Specialty & Generic

Hanmi Pharm Co., Ltd.

128940KRX₩415,000+₩26,500 (+6.82%)Market closed

Price Chart

Daily

Key facts

Market Cap
₩5.32T
P/E
31.0x
P/B
4.21x
ROE
14.5%

Hanmi Pharm Co., Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic · FY 2025

Hanmi Pharm Co., Ltd. is a prominent pharmaceutical company known for its innovative approach to drug development and manufacturing in South Korea. Its core function centers around researching and producing a wide array of pharmaceuticals, including innovative therapies and generics, aiming to treat a multitude of health conditions. Hanmi Pharm focuses on several therapeutic areas such as oncology, diabetes, and cardiovascular diseases, driving advancements with its cutting-edge proprietary technologies. The company is renowned for its robust R&D initiatives, evidenced by numerous patents and significant investments into creating biopharmaceuticals that cater to global health needs. In the financial market, Hanmi Pharm represents a staple in the healthcare sector, reflecting the dynamic nature of medical innovation and healthcare demand. With its headquarters strategically located in South Korea, the company not only impacts local pharmaceutical landscapes but also positions itself as a key player in the global market through strategic partnerships and international collaborations. Hanmi Pharm Co., Ltd. plays a crucial role in advancing medical treatments, contributing significantly to the pharmaceutical industry's growth and innovation.

CEO
박재현
Employees
2,270

Company Statistics

Valuation

P/E
31.0x
P/B
4.21x
P/S
3.40x
EV/EBITDA
15.4x
P/FCF
54.5x

Margins

Gross
57.1%
EBITDA
24.1%
Operating
16.7%
Pre-Tax
13.8%
Net
12.1%

Returns

ROA
9.0%
ROE
14.5%
ROIC
11.1%

Growth (CAGR)

Rev 3Yr
5.1%
Rev 5Yr
7.5%
Op Inc 3Yr
17.7%
Net Inc 3Yr
22.6%

Financial Health

Cash & Cash Equivalents
₩108.27B
Net Debt
₩606.47B
Debt/Equity
50.2%
Interest Cov
—

Profile

Revenue
₩1.55T
Shares Out
12.8M
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Hanmi Pharm Co., Ltd. (128940) Stock Forecast 2026 ₩415,000 — Price, Financials & Analyst Targets | AlphaLenz